Literature DB >> 3940633

Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum (II) in vivo and in vitro.

A K Lichtenstein, D Pende.   

Abstract

To investigate the immunomodulating properties of cis-diamminedichloroplatinum (II) (CDDP), we studied the drug's effects on natural killer (NK) lymphocyte cytotoxicity. i.p. injections of CDDP (2-6 mg/kg) into adult mice significantly enhanced cytolysis of YAC-1 and K562 targets mediated by peritoneal and spleen cells. Lysis of the NK-resistant targets P815, EL-4, MOT, and RAJI was not increased, nor was the lysis of a YAC variant which had been specifically rendered resistant to NK lysis. Activated cytotoxicity was first noted 24 h after injection and returned to baseline by 7 days. Although i.p. injection enhanced peritoneal and spleen cell lysis, i.v. injection only activated spleen cells. Two analogues of CDDP, carbo- and iproplatin, effectively enhanced NK activity, but transplatin had no effect. Activated effector cells were non-adherent to nylon wool and serum-coated plates; they co-separated with lymphocytes on Percoll gradients, and they expressed asialo GM1 determinants. Incubation of targets with CDDP for 1 or 18 h significantly increased their sensitivity to lysis by normal murine spleen cells. These data indicate that CDDP has potent effects on NK cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3940633

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice.

Authors:  C S Johnson; M J Chang; W D Yu; R A Modzelewski; J R Grandis; D R Vlock; P Furmanski
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

2.  Effect of cisplatin upon expression of in vivo immune tumor resistance.

Authors:  E D Crum
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

3.  MMP9 Expression Correlates With Cisplatin Resistance in Small Cell Lung Cancer Patients.

Authors:  Longqiu Wu; Xiangcai Wang; Xin He; Qiang Li; Qian Hua; Rongrong Liu; Zhengang Qiu
Journal:  Front Pharmacol       Date:  2022-04-01       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.